{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:19:55Z","timestamp":1792552795971,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) represents an important research topic. Despite the potential benefits of this approach, the inflammatory responses and adverse events associated with neoadjuvant chemoimmunotherapy can present technical challenges and compromise a planned resection. This study assessed the safety and feasibility of neoadjuvant chemoimmunotherapy followed by surgery for resectable NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was conducted from May 2019 to March 2021. Patients who were age 18 years or older, were diagnosed with stage Ib\u2013IIIb NSCLC, and received neoadjuvant chemoimmunotherapy followed by surgery were included. Demographic information, clinical and pathologic characteristics, data about neoadjuvant therapy, and surgical details were collected by retrospective chart review. Toxicity profiles were collected retrospectively or by telephone follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients were included in this study. The median age was 56 years (range, 48\u201372 years), and 18 patients (90%) were men. Squamous carcinoma (14\/20, 70%) was the most common cancer type, followed by adenocarcinoma (4\/20, 20%), adenosquamous carcinoma (1\/20, 5%), and large cell neuroendocrine carcinoma (1\/20, 5%). All patients received two to four cycles of neoadjuvant therapy, and the median interval between final therapy and surgery was 49 days (range, 23\u2013133 days). Computed tomography evaluation after neoadjuvant therapy showed partial response in 15 patients (75%) and stable disease in 5 (25%). Final pathologic examinations showed major pathologic response in eight patients, including pathologic complete response in five (25%). Most patients (18\/20, 90%) had reduced pathologic staging. Twelve patients (60%) underwent open thoracotomy; the other eight patients underwent minimally invasive surgery, which was uneventful and without intraoperative conversion to open thoracotomy. No perioperative deaths occurred, and only seven patients (35%) developed postoperative complications. Most patients experienced only grade 1\u20132 adverse effects and laboratory abnormalities during neoadjuvant therapy, and no grade 3 or worse adverse effects or laboratory abnormalities occurred. No patients experienced surgical delays as a result of immune-related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Preoperative administration of chemoimmunotherapy for patients with resectable NSCLC was safe and feasible.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.684070","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T05:43:21Z","timestamp":1633585401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Yan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant Vinorelbine Plus Cisplatin Versus Observation in Patients With Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.001","article-title":"Efficacy and Safety of Neoadjuvant Immunotherapy in Resectable Nonsmall Cell Lung Cancer: A\u00a0Meta-Analysis","volume":"147","author":"Jia","year":"2020","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/JTO.0b013e31815e5d9a","article-title":"Neoadjuvant Chemotherapy With Gemcitabine-Containing Regimens in Patients With Early-Stage Non-Small Cell Lung Cancer","volume":"3","author":"Detterbeck","year":"2008","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Participant Data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer: Results of the MRC LU22\/NVALT 2\/EORTC 08012 Multicentre Randomised Trial and Update of Systematic Review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as Neoadjuvant Therapy for Resectable Stage II-IIIA Non-Small Cell Lung Cancer: A Phase II Study","volume":"161","author":"Zhang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586596","article-title":"Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial Results of Pulmonary Resection After Neoadjuvant Nivolumab in Patients With Resectable Non-Small Cell Lung Cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant Atezolizumab and Chemotherapy in Patients With Resectable Non-Small-Cell Lung Cancer: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J\u00a0Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.10.002","article-title":"Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer","volume":"17","author":"Singh","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575472","article-title":"Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-Small Cell Lung Cancer","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and Its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/BF01192200","article-title":"Tumour Regression in Non-Small-Cell Lung Cancer Following Neoadjuvant Therapy","volume":"123","author":"Junker","year":"1997","journal-title":"Histol Assessment J Cancer Res Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small-Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 Inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00262-021-02847-1","article-title":"The Surgical Perspective in Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer","volume":"70","author":"Jiang","year":"2021","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318252d022","article-title":"Resection Rate and Outcome of Pulmonary Resections for Non-Small-Cell Lung Cancer: A Nationwide Study From Iceland","volume":"7","author":"Thorsteinsson","year":"2012","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2020-63","article-title":"Expert Consensus on Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer","volume":"9","author":"Liang","year":"2020","journal-title":"Trans Lung Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.684070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T05:43:23Z","timestamp":1633585403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.684070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":30,"alternative-id":["10.3389\/fonc.2021.684070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.684070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"article-number":"684070"}}